Skip to main content
ASPHO Logo
Menu Journal My Account Contact Join/Renew
Login
  • Meetings & Events
    • Conference
      • 2023 Conference
        • 2023 Conference
        • Hotel and Travel
        • Health and Safety
        • Registration
        • Schedule
        • Continuing Education
        • Corporate Symposia
        • Commercial Support
          • Virtual Exhibitor and Engagement Opportunities
        • Back to Meetings
      • Meetings Archive
      • Press | 2018 Conference
      • 2018 Call for Papers and Posters
        • Back to Meetings
        • 2019 Conference
        • Schedule of Events
        • Registration Rates
        • Conference Planning Committee
        • Conference Hotel and Travel
        • Faculty
        • 2019 Call for Papers and Posters
        • Continuing Education
        • PBMTC
        • Accepted Papers and Posters
        • Corporate Symposia
        • MOC Opportunities
        • App - Thank you for Attending
        • 2019 Attendee List
      • 2019 Call for Workshops
      • 2018 Conference
        • Schedule of Events
        • Accepted Papers and Posters
      • 2016 Annual Meeting
        • Overview
        • Attendee List
        • ASPHO Virtual Bag
        • Corporate Forum Symposia/Education Theaters
        • Accepted Papers and Posters
          • Accepted A-G
          • Accepted H-M
          • Accepted N-Z
          • 2016 Searchable Abstract Database
        • Exhibit Hall
        • Sponsors
        • Annual Meeting Brochure
        • 2017 Call for Workshops
        • Virtual Bag
        • Schedule of Events
        • Continuing Education
        • Attendee List
        • 2017 Searchable Abstract Database
        • Accepted Papers and Posters
        • Corporate Forum Symposia/Education Theater
        • Travel
        • Program Committee
        • Commercial Support
        • Exhibit with ASPHO
    • Review Course
      • 2023 Review Course
        • Review Course 2023 Cancellation Policies and Disclosures
      • Anderson 2019
      • McClain 2019
      • Adams 2019
      • Moran 2019
      • Effinger 2019
      • Fangusaro 2021
      • Brown 2021
      • Young 2021
      • Harker-Murray 2021
      • Effinger 2021
      • Pai 2021
      • Grace 2021
      • Rogers 2021
      • Anderson 2021
      • Powers 2021
      • McClain 2021
      • Neunert 2021
      • Fleming 2021
      • Mullen 2021
      • Pommert 2021
      • Meade 2021
      • Greengard 2021
      • Fox 2021
      • Bercovitz 2021
      • Brock 2021
      • Adams 2021
      • Loh 2021
      • O'Brien 2021
      • Walterhouse 2021
      • Pulsipher 2021
      • Oberley 2021
      • Rodriguez-Galindo 2021
      • Kesselheim 2021
      • Frei-Jones 2021
      • Allen 2021
      • 2015 Online Review Course CME Certificates
      • 2019 Planning Committee
      • 2019 Schedule
      • 2019 Travel
      • 2019 Review Course Early Career
      • 2019 Review Course Directors
        • 2019 Review Course Faculty
      • Oberley 2019
      • O'Brien 2019
      • Pai 2019
      • Pulsipher 2019
      • Rodriguez-Galindo 2019
      • Rogers 2019
      • Walterhouse 2019
      • Young 2019
      • Park 2019
      • Malec 2019
      • Evaluations
      • Brown 2019
      • Allen 2019
      • Fangusaro 2019
      • Fleming 2019
      • Frei-Jones 2019
      • Grace 2019
      • Harker-Murray 2019
      • Heeney 2019
      • Kesselheim 2019
      • Loh 2019
      • Mascarenhas 2019
      • Neunert 2019
      • Fangusaro 2023
      • Adams 2023
      • Neunert 2023
      • Oberley 2023
      • Grace 2023
      • Effinger 2023
      • Nakano 2023
      • Brock 2023
      • Harker-Murray 2023
      • Meade 2023
      • Fleming 2023
      • Kesselheim
      • Kumar 2023
      • Anderson 2023
      • Malogolowkin 2023
      • Pommert 2023
      • Bercovitz 2023
      • Frei-Jones 2023
      • O'Brien 2023
      • Pai 2023
      • Young 2023
      • Fox 2023
      • Powers 2023
      • Pulsipher 2023
      • McClain 2023
      • Loh 2023
      • Greengard 2023
      • Frazier 2023
      • Brennan 2023
      • Walkovich 2023
      • Browning 2023
      • 2023 Faculty
        • Office Hours
        • Learning Objectives and CME
        • Faculty
        • Planning Committee
      • Mullen 2023
      • 2023 Schedule
      • 2023 Learning Objectives and CME
      • Review Course Archive
    • Events Calendar
  • Knowledge Center
    • Products
      • KARE Toolkit: Knowledge and Assessment Resources
        • CME for KARE
        • CME for RC On-Demand
        • CME for PHO Review Course On Demand
        • CME for KARE Plus
        • CME for KARE Plus Hematology
        • CME for KARE Plus Oncology
        • The KARE Toolkit - Index of Topics
      • Recordings
      • Webinars
      • ASPHOcast
      • 2020 Compensation Survey
    • Online Review Course
    • Pediatric Blood & Cancer
      • Access Journal
      • Online Access Instructions
    • ASPHO eNews
      • August 2015 Enews
      • June 2015 Enews
      • April 2015 Enews
      • February 2015 Enews
      • December 2014 Enews
      • October 2014 Enews
      • August 2014 Enews
      • June 2014 Enews
      • April 2014 Enews
      • February 2014 Enews
      • December 2013 Enews
      • October 2013 Enews
      • August 2013 Enews
      • June 2013 Enews
      • April 2013 Enews
      • February 2013 Enews
      • October 2014 Enews
      • October 2015 Enews
      • December 2015 Enews
      • February 2016 Enews
      • April 2016 Enews
      • June 2016 Enews
        • DSIG Student Registration
      • August 2016 Enews
      • October 2016 Enews
      • December 2016 Enews
      • February 2017 Enews
      • April 2017 Enews
      • June 2017 Enews
      • August 2017 Enews
      • October 2017 Enews
      • December 2017 Enews
      • February 2018 Enews
      • April 2018 Enews
      • June 2018 Enews
      • August 2018 eNews
      • October 2018 eNews
      • February 2019 eNews
      • Member Insights: eNews 2018 Highlights
      • April 2019 eNews
      • June 2019 eNews
      • August 2019 eNews
      • October 2019 eNews
      • December 2019 eNews
      • February 2020 eNews
      • April 2020 eNews
      • June 2020 eNews
      • August 2020 eNews
      • October 2020 eNews
      • December 2020 eNews
      • April 2021 eNews
      • June 2021 eNews
      • August 2021 eNews
        • August 2021 President's Message
      • December 2021 eNews
      • February 2022 eNews
      • April 2022 eNews
      • June 2022 eNews
      • August 2022 eNews
      • October 2022 eNews
      • December 2022 eNews
      • February 2023 eNews
    • Pediatric Blood & Cancer - Call for Applications for Deputy Editor
    • October 2015 Enews
    • Advocacy Sample
    • News Briefs
    • Health Policy & Advocacy
      • 2016 August Advocacy Brief
      • 2016 December Advocacy Brief
      • 2017 February Advocacy Brief
      • 2017 May Advocacy Brief
      • 2017 September Advocacy Brief
      • 2017 November Advocacy Brief
      • 2018 Advocacy Brief - March
      • Contact Your Members of Congress
      • 2018-Advocacy-Brief-June
      • 2018-Advocacy-Brief-September
      • Advocacy Brief December 2018
      • 2019 Advocacy Brief - March
      • March 2019 Advocacy Brief
      • June 2019 Advocacy Brief
      • September 2019 Advocacy Brief
      • March 2020 Advocacy Brief
      • June 2020 Advocacy Brief
      • September 2020 Advocacy Brief
      • December 2020 Advocacy Brief
      • June 2021 Advocacy Brief
      • September 2021 Advocacy Brief
      • March 2022 Advocacy Brief
      • June 2022 Advocacy Brief
      • September 2022 Advocacy Brief
    • 2017 Workforce Survey Report
    • Help Fund the STAT Act
    • Practice and Quality
      • Choosing Wisely®
      • Position Paper
      • Endorsements
      • ASPHO Endorsements member only
  • Career Development
    • Mentoring
      • Early Career Mentoring
    • Awards
      • Distinguished Career Award
      • Oski Memorial Lectureship
      • International Travel Awards
      • Arceci Innovation Award
      • Buchanan Lectureship
      • Young Investigator Award
      • Young Investigator Form
      • EC Travel Stipend Form
      • Early Career Travel Stipend
      • Advanced Practice Provider Award
      • Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship
    • Career Center
    • Fellowship Resources
      • Post-PHO Fellowship Program Directory
      • Fellowship Program Directors' Resources
    • Certification
      • Continuing Medical Education
      • advocating for moc
      • ABP MOC Letter Nov 2015
      • ABP Hematology/Oncology Content Outline
    • 2019 ASPHO Award Recipients
    • Workforce
  • Membership
    • Who Belongs
    • Benefits
    • Join Us
    • Renew
    • Membership Application
    • Fellows Group Application
    • Member Community
    • Find a Member
    • Special Interest Groups
      • Adolescent and Young Adult SIG
      • Advanced Practice Provider SIG
      • Cancer Predisposition SIG
      • Clinical Immunology SIG
      • Diversity SIG
        • 2017 DSIG Travel Award
      • Global Hem Onc SIG
      • Hemoglobinopathy SIG
      • Hospitalist Medicine SIG
      • Informatics, Innovation and Entrepreneurship SIG
      • Integrative Pediatric Hematology/Oncology SIG
      • Palliative Care SIG
      • Physician Scientist SIG
      • Quality Improvement and Patient Safety SIG
      • Small Program SIG
      • Vascular Anomalies SIG
      • Clinical Immunology SIG Webinar
      • Well-Being SIG
    • Enriching the Future
      • ETF Donors
      • ETF FAQ
      • ETF Programs
      • ETF Award Recipients
      • Donate
    • Stay Connected with ASPHO
    • New Member
    • Trainee Membership Level
    • Strengthen Your Everyday Practice
  • About
    • Governance
      • 2017 Election Nominations
      • 2019 Board and Nominating Committee members
      • Board of Trustees
      • Leadership Development & Election Process
      • Nominating FAQs
      • Strategic Plan
        • Leadership Domain
        • Education Domain
        • Career Domain
        • Administration Domain
      • Volunteer Opportunities
        • Early Career Council
    • Policies
      • Advertising Sponsorship
      • Support of CME
      • Committee Policies, Responsibilities, and Resources
      • Conflict of Interest and Disclosure for Volunteers
      • Distinguished Career Award Eligibility Criteria
      • Diversity Statement
      • Investment
      • Member Mailing List
      • Oski Eligibility Criteria
      • Presidential Stipend
      • Records Retention
      • Reserve Fund
      • Reviews and Endorsements
      • Speaker Reimbursement
      • Surveying Members
      • Whistleblower
      • Workshop Session
      • Young Investigator Award
      • Early Career Travel Stipend
      • Buchanan Lectureship Eligibility
      • ASPHO Statements
    • Terms of Use
    • Contact Us
    • 2016 Election Nominations
    • 2015 Election Candidates
    • FDA Approves Dinutuximab
    • Q&A Amy Billett
    • Fund Raising Policy
    • Support and Advertising
      • Exhibit
      • Advertising
      • Industry Relations Council
      • Grants
    • Diversity & Inclusion
    • Donate
  • 2017 Annual Meeting Session Recordings
  • 2018 Annual Meeting Session Recordings
  • George R. Buchanan Lectureship Award Presentation
  • Cancer Predispositions in Clinical Practice
  • Evidence and Equipoise in Pediatric Thrombosis - Updates from Randomized Controlled Trials
  • Playing on Our Strengths - Developing Interprofessional Teams in Pediatric Hematology-Oncology
  • Providing Optimal Pediatric Palliative Care: Overcoming the Barriers
  • When in Quebec, Do What the Quebecers Do (Part Deux) - It's All About Platelets!
  • Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Pediatric Patients with ALL in the era of Tyrosine Kinase Inhibitors, Novel Immunotherapies and 'MRD Status'
  • Award Presentations
  • Hemophilic Arthropathy, More Than Meets the Eye: Advances in Early Disease Detection from Clinical Tools to Musculoskeletal Imaging
  • ZFNs, CrispR/Cas9 and TALENS- Oh My!
  • Collaboration in the Treatment of Liver Tumors
  • Leukemia
  • Solid Tumors/Lymphoma
  • Hematology I
  • Beyond Antibodies and CAR T Cells: Challenges and Opportunities in Manipulating the Pediatric Cancer Immunome
  • Blood Clots in Sick Kids: A critical mini-review of venous thrombo-embolism in selected high-risk pediatric populations
  • It's not just about Diversity: Improving the Outcomes for All by Moving toward Equity
  • Children's Oncology Group (COG)
  • Outcomes Research
  • Social Media: The Good, The Bad, and Beyond
  • Sickle Cell Disease in the AYA population: Management Challenges for the Pediatric Hematologist
  • Molecularly Defined Rare Pediatric Sarcomas: An Update for the General Oncologist
  • Mechanisms of Tumor Microenvironment Immune Mediated Resistance and Methods of Therapeutic Circumvention
  • Behind the Scenes at Pediatric Blood & Cancer: Everything You Always Wanted to Know About Getting Published
  • New Insights in Inherited Hematologic Diseases
  • Changing Workforce of Pediatric Hematology/Oncology
  • New Diagnostic and Therapeutic Approaches of Opportunistic (Viral/Fungal) Infections in the Pediatric Cancer Patient
  • New Mutations and Targeted Therapies in Langerhans Cell Histiocytosis
  • Physician, Sustain Thyself: Building Resilience to Prevent Burnout
  • Practicing Precision in Pediatric Oncology: Three Perspectives
  • What's Happening in DC? A Look at ASPHO Advocacy Efforts
  • Critical Care of the Immunocompromised Pediatric Hematology/Oncology Patient
  • Brain Tumors
  • Hematology II
  • Sponsor, Exhibit, and Advertise
    • Exhibits
    • Advertising
    • Industry Relations Council
    • Exhibits Adveritising
  • Ward Testing OSE
  • 2018 Session | George R. Buchanan Lectureship Award Presentation
  • 2018 Session | Plenary Paper Session 2001-2002
  • 2018 Session | St. Baldrick's Foundation Robert J. Arceci Innovation Award Announcement
  • 2018 Session | Plenary Session—Health Care in the Current Political Climate: Stormy Days Ahead?
  • 2018 Session | Pediatric Ependymoma: The Science Driving Patient Care
  • 2018 Session | Iron: Let's Get Pumped
  • 2018 Session | Extracellular Vesicle Trafficking—Biology and Translational Impact in Hematology and Cancer
  • 2018 Session | Relapsed, Refractory, Metastatic Bone Sarcomas: New Insights on Pathogenesis, Prognosis and Treatment
  • 2018 Session | Alpha Thalassemia—A Growing Public Health Disease with Changing Landscape of In-Utero and Post-Natal Therapy
  • 2018 Session | Decision Making in Benign Hematology: Living in a World Without Randomized Trials
  • 2018 Session | Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship
  • 2018 Session | Early Career Travel Stipend Awards
  • 2018 Session | Young Investigator Award Presentations
  • 2018 Session | Management of Extracranial Germ Cell Tumors in Adolescent and Young Adult Population
  • 2018 Session | Challenging Hematologic Complications Post–Stem Cell Transplantation and Beyond
  • 2018 Session | Advanced Symptom Management and End-of-Life Care: Multidisciplinary Primary Palliative Care for Pediatric Hematologists/Oncologists
  • 2018 Session | Paper Session - Solid Tumor
  • 2018 Session | Paper Session - Hematology
  • 2018 Session | Vascular Anomalies: The Great Mimickers
  • 2018 Session | Addressing Sexual Health in Adolescent and Young Adult Patients: What You Should Know as a Pediatric Hematology/Oncology Care Provider
  • 2018 Session | Navigating Intravascular Bottlenecks: A Critical Mini-Review of Pediatric Venous Thromboembolism in the Setting of an Anatomical Thrombophilia
  • 2018 Session | Paper Session - Children's Oncology Group (COG)
  • 2018 Session | Paper Session - Hematology Science
  • 2018 Session | Can Late Effects be Prevented in Pediatric Oncology?
  • 2018 Session | Clash of the Titans: Debates on Best Management of Patients with Bleeding Disorders
  • 2018 Session | Providing Effective Feedback: The Currency of Conflict Resolution
  • 2018 Session | Recent Advances and New Approaches to Rare Hematological Malignancies
  • 2018 Session | Primary and Secondary Stroke Prevention in Sickle Cell Disease: The Debate
  • 2018 Session | Combating an Unmet Need: Psychosocial Health
  • 2018 Session | Renal Tumors Beyond Wilms
  • 2018 Session | Pediatric and Neonatal Transfusion Medicine
  • 2018 Session | Mobile Applications in Clinical Practice
  • 2018 Session | Presidential Symposium—Partnering with Patients and Families to Improve Research and Clinical Decision-making
  • 2018 Session | Review of Rare Pediatric Head and Neck Tumors for the General Oncologist
  • 2018 Session | Emerging Therapies in Hemophilia
  • 2018 Session | How Should You Treat That Bug? A Debate About Antimicrobial Management in Fever and Neutropenia
  • 2018 Session | Paper Session with Luminary Investigator - Leukemia
  • 2018 Session | Paper Session with Luminary Investigator - Hematology
  • 2018 Session | Frank A. Oski Memorial Lectureship Award Presentation
  • December 2018 eNews
  • 2019 Session | Splenectomy - The Great Debate
  • 2019 Session | DICER1: Updates on Biology and Clinical Management
  • 2019 Session | Burnout in Pediatric Hematology/Oncology: Moving from Discussion to Action
  • 2019 Session | Diagnostic and Management Conundrums Surrounding Women with Heavy Menstrual Bleeding and Underlying Bleeding Disorders
  • 2019 Session | All That Glitters is Not Gold – How We Differentiate Primary HLH from Fake News
  • Models for International Pediatric Oncology Outreach
  • 2019 Session | Navigating Genetic Testing in the Pediatric Hematology Setting
  • 2019 Session | Radiation Therapy for Pediatric Cancer Patients: Updates and New Modalities
  • 2019 Session | The Microbiome: What Is It and Why Do We Care?
  • 2019 Session | Brain Attack: Therapeutic Advances in Neonatal and Childhood Stroke
  • 2019 Session | Advances in Pediatric AML
  • 2019 Session | Improving Medication Adherence for Adolescents and Young Adults: Is Technology the Answer?
  • 2019 Session | Metabolism in Pediatric Hematology/Oncology - Presidential Symposium
  • 2019 Session | Too Much of a Good Thing – Myeloproliferation in Children
  • 2019 Session | Multiple Bony Lytic Lesions, but Not Langerhans Cell Histiocytosis (LCH) – Now What?
  • 2019 Session | Savior Siblings: Medical, Ethical, and Psychosocial Considerations in using Preimplantation Genetic Diagnosis (PGD) to Ensure a Matched Sibling Donor for Hematopoietic Stem Cell Transplantation (HSCT)
  • 2019 Session | George R. Buchanan Lectureship Award Presentation
  • 2019 Session | 2019 St. Baldrick’s Foundation Robert J. Arceci Innovation Award Announcement and Past Recipient Presentation
  • 2019 Session | Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship Announcement and Frank A. Oski Memorial Lectureship Award Presentation
  • 2019 Session | New Paradigms for Severe Aplastic Anemia: Genetic Screening, Eltrombopag, and Up Front Unrelated Donor BMT
  • 2019 Session | Not Too Young for That Cancer: Adolescent and Young Adult Carcinomas
  • 2019 Session | Transforming the Treatment of Chronic Pain
  • 2019 Session | Putting an End to End Organ Damage in Sickle Cell Disease
  • 2019 Session | Defining Pediatric MDS: A Morphologic or Molecular Diagnosis?
  • 2019 Session | The Power of One: Present Challenges in Treating Rare Diseases
  • 2019 Session | Hematological Manifestations of Immune Deficiencies and Dysregulatory Disorders: When should you look harder for underlying causes of Autoimmune Cytopenias?
  • 2019 Session | Oncofertility Programs: More Than Just Sperm Banking
  • 2019 Session | The (Financial) Cost of a "Cure"
  • 2019 Session | (2001) Potential Utility of MRD to Identify Relapse in pALL Patients Treated with Tisagenlecleucel
  • 2019 Session | (2002) Lentiglobin Gene Therapy in Transfusion-Dependent Β-Thalassemia Patients with Non-β0/β0 Genotypes
  • 2019 Session | (2003) Mechanisms of Resistance to the Type II JAK2 Inhibitor CHZ868 in B-Cell Acute Lymphoblastic Leukemia
  • 2019 Session | (2004) Discovering Noncoding Genetic Elements that Regulate Globin Synthesis
  • 2019 Session | (2005) Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis: Safety & Efficacy
  • 2019 Session | (2006) Modeling IKZF1 Lesions in B-cell Acute Lymphoblastic Leukemia Reveals Potential Therapeutic Targets
  • 2019 Session | (2007) Prognostic Determinants in Childhood T-cell Acute Lymphoblastic leukemia: Results of DFCI 05001
  • 2019 Session | (2008) Gap Junction Interference increases Apoptosis in ALL cells and augments effects of Antimetabolites
  • 2019 Session | (2009) Hydroxyurea Lowers Tricuspid Regurgitant Jet Velocity in Children with Sickle Cell Anemia
  • 2019 Session | (2010) Novel Next-Generation Sequence based Assay for Non-Invasive Prenatal Testing of Sickle Cell Disease
  • 2019 Session | (2011) Gabapentin for Pain in Sickle Cell Disease: Results of a Randomized Phase II Clinical Trial
  • 2019 Session | (2012) Quality of Life is the most important Indication for Second-Line ITP Treatment in Children
  • 2019 Session | (2013) BCL2-Inhibitor Response in Neuroblastoma: Biomarkers and Therapy Resistance
  • 2019 Session | (2014) The Clinical Application of Molecular Testing in Pediatric Solid Tumors: An Institutional Experience
  • 2019 Session | (2015) Enhancing Tumor Directed T Cells with an Interleukin-7 Signal Modulator
  • 2019 Session | (2016) Epigenome Screening Identifies Transcriptional Elongation as Therapeutic Vulnerability in DIPG
  • 2019 Session | (2017) Levofloxacin Prophylaxis
  • 2019 Session | (2018) Renal Tumors: Future Roadmap
  • 2019 Session | (2019) Soft Tissue Sarcoma
  • 2019 Session | (2020) Realizing Effectiveness across Continents with Hydroxyurea (REACH): A Prospective Multi-National Trial of Hydroxyurea for Sickle Cell Anemia in Sub-Saharan Africa
  • 2019 Session | (2021) Leucine for the Treatment of Transfusion Dependence in Patients with Diamond Blackfan Anemia
  • 2019 Session | (2022) A Phase 1/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds
  • 2019 Session | (2023) Peripherally Inserted Central Catheters (PICCs), the Leading Cause of Central Venous Catheter Associated Thrombosis in Children
  • 2019 Session | The Role of Survivorship Research in Advancing Childhood Cancer Care and Quality of Survival
  • 2019 Session | (2024) Septic Shock (SS) Incidence in National ALL & AML Cohorts using Administrative & Clinical Trial Data
  • 2019 Session | (2025) Nelarabine Abrogates Relapse Rates in CNS-3 T-ALL: A Report from Children’s Oncology Group AALL0434
  • 2019 Session | (2026) Current Cancer Survivorship Practices: A Report from the Children’s Oncology Group (COG)
  • 2019 Session | (2027) Intra-Arterial Chemotherapy for Retinoblastoma: A 7-year Single Institution Experience
  • 2019 Session | Advancing Discovery in Hematology: Bench to Bedside? No. Bedside to Bench to Bedside...
  • 2019 Session | (2028) The Shwachman Diamond Syndrome Registry: Hematologic Complications
  • 2019 Session | (2029) Characteristics and Outcomes of Unprovoked Venous Thromboembolism in the Pediatric Population
  • 2019 Session | (2030) Third Party VST are an effective Therapy for the Treatment of BK-Virus Reactivation after Transplant
  • 2019 Session | (2031) Inhibition of Nemo-Like Kinase improves Erythropoiesis in Models of Diamond Blackfan Anemia
  • 2019 Annual Meeting Session Recordings
  • CI SIG Webinar
  • October 2021 eNews

ASPHO's 30th Annual Meeting

April 26-29, 2017
Montréal, Québec, Canada


Wednesday
| Thursday | Friday | Saturday | Conference Brochure

Sessions marked with an (M) are for MOC. 

Wednesday, April 26

7:30–11:00 am

(PC01) Vascular Anomalies Primer Course
Room 519


Moderator: Ionela Iacobas, MD Co-chairs: Cameron C. Trenor, MD; Francine Blei, MD

Objectives:

  1. Improve the pediatric hematologist/oncologists understanding of the classification of vascular anomalies.
  2. Provide an understanding of treatment options for vascular tumors and malformations.
  3. Provide an understanding of associated syndromes and genetic discovery to improve clinical acumen and improve the understanding of the use of surgery and interventional radiology in the treatment of vascular anomalies.
  4. Develop an understanding of the pathological differences of varied vascular anomalies.

The Vascular Anomalies Special Interest Group was started in 2013, and consistently has seen participation by 10%–15% of annual meeting registrants. This field historically has been dominated by surgeons, interventional radiologists, and dermatologists. Because of recent successes in medical therapies led by pediatric hematology/oncology providers and the implementation of collaborative research programs, however, the role of the pediatric hematologist/oncologist in this field has become clear. There is an acute need for our community to acquire basic knowledge about the diagnosis and management of these conditions.

Advanced registration is recommended. The registration fee is $25.

Supported in part by vascular anomalies patient support groups.

Introduction and Classification of Vascular Anomalies
Francine Blei, MD

Pathology and Genetics of Vascular Anomalies
Adrienne M. Hammill, MD PhD

Associated Syndromes
Cameron C. Trenor, MD

Visual Diagnosis Case Presentations
Julie Powell, MD

Interventional Management of Vascular Anomalies
Josee Dubois, MD

Surgical Management of Vascular Anomalies
Steven Fishman, MD

Medical Management of Vascular Anomalies
Denise M. Adams, MD

No relevant financial relationships to disclose; discussion of off-label drug use: Ionela Iacobas; Josee Dubois; Denise M. Adams

No relevant financial relationships to disclose and no discussion of off-label drug use: Adrienne M. Hammill; Steven Fishman

Relevant financial relationships to disclose and no discussion of off-label drug use: Francine Blei- Pierre Fabre: Research Funding (non-product related), educational research non-product related grants; Pierre Fabre: Advisory board member, honoraria; Julie Powell - Pierre Fabre Dermatology: honorarium, speaker, consultant, investigator

Relevant financial relationships to disclose; discussion of off-label drug use: Cameron C. Trenor-Pfizer: Principal investigator, no compensation received

7:45 am–8:30 pm

Pediatric Blood and Marrow Transplant Consortium Meeting (PBMTC) (Le Westin)

11–11:30 am

Vascular Anomalies Special Interest Group (VSIG)
Room 519

Co-chairs: Francine Blei, MD; Cameron C. Trenor, MD

The meeting will provide the Research, Practice, and Education Committees’ ongoing studies and brainstorm for new projects. Advanced registration is recommended.

11:30–1:00 pm

Corporate Lunch Symposium
Room 520ABDE

Click here for details and registration. 

1-2:30 pm

(SE01) George R. Buchanan Lectureship Award Presentation
Room 517D

Jeffrey M. Lipton, MD PhD

Big Lessons from a Small Disease: “Stumbling from failure to failure with no loss of enthusiasm."

Objectives:

  1. Discuss the roles of mentorship and collaboration in forging a career.
  2. Relate that the importance of a rare disease is often inversely proportional to its incidence.

Diamond Blackfan anemia is a very rare inherited bone marrow failure syndrome; incidence 5 -10 per million live births. The disorder, first described in 1936, is characterized in classic cases by erythroid failure resulting in severe anemia, birth defects and a marked predisposition to cancer. The majority of genetically defined cases result from mutations or deletions in one of more than 15 genes encoding either a small or large subunit – associated ribosomal protein resulting in haploinsufficiency of that ribosomal protein. The somewhat restricted phenotype and the predisposition to cancer resulting from a defect in translation are both intriguing and unexplained. This talk will review clinical and laboratory research over the past 40 years that has led to our current understanding of this disorder. Emphasis will be placed on the influence of mentorship and collaboration in the discovery upon which our current knowledge is based.

No relevant financial relationships and no discussion of off-label drug use.

(PS4001-4002) Plenary Paper Session

Moderators: Denise M. Adams, MD; Donald L. Yee, MD MS

Objectives:

  1. Discuss new approaches related to diagnosis and treatment in pediatric hematology/oncology.
  2. Examine current research outcomes from a variety of the latest in basic and clinical research.

The 2017 Program Committee has chosen the abstracts listed below as among the best submissions.

Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells (4001)
Giedre Krenciute, PhD

P2Y12 Receptor Function and In Vivo Platelet Response to Cangrelor in Neonates with Cyanotic Congenital Heart Disease (4002)
Thomas Diacovo, MD

No relevant financial relationships and no discussion of off-label drug use: Giedre Krenciute

Relevant financial relationships and discussion of off-label drug use: Thomas Diacovo - The Medicine Compnay; Principle Investigator, research grant

2:45–4:15 pm

(A1) Cancer Predispositions in Clinical Practice (M)
Room 517D

Moderator: Christopher C. Porter, MD

Objectives:

  1. Identify cancers and other features associated with predisposition syndromes and the genes involved in predisposition syndromes.
  2. Discuss the unique aspects of genetic counseling for children and families with cancer predisposition syndromes (as compared to adults).
  3. Develop tumor surveillance strategies for children with cancer predisposition syndromes.

Cancer predisposition syndromes are being diagnosed at increasing rates and new ones continue to be discovered. However, optimal counseling, testing, and management strategies are undefined. Pediatric oncologists should be knowledgeable about the presentation and genetics of cancer predisposition syndromes and the unique aspects of genetic counseling for children and families with cancer predisposition syndromes (as compared with adults) and be able to develop tumor surveillance strategies for children with cancer predisposition syndromes.

Cancer Predisposition and Kids: Genes, Family History, and Physical Exam
Joshua D. Schiffman, MD

Genetic Counseling for Children and Families with Cancer Predisposition Syndromes
Kami Wolfe Schneider, MS CGC

Tumor Surveillance Strategies
Garrett M. Brodeur, MD

No relevant financial relationships to disclose; discussion of off-label drug use: Christopher C. Porter; Kami Wolfe Schneider; Garrett M. Brodeur

Relevant financial relationships to disclose and no discussion of off-label drug use: Joshua D. Schiffman- ItRunsInMyFamily.com: Founder, stock

(A2) Evidence and Equipoise in Pediatric Thrombosis— Updates from Randomized Controlled Trials (M)
Room 524

Moderator: Cameron C. Trenor, MD

Objectives:

  1. Discuss challenges in design and implementation of pediatric thrombosis clinical trials.
  2. Recognize areas of active investigation in pediatric thrombosis and understand the data supporting studies compared to standard of care.

Despite the increasing attention to thrombosis in children, most evidence guiding pediatric practice is taken from adult data and clinical experience. In recent years, randomized controlled trials dedicated to pediatric patients have begun to address major questions in thrombosis. This session will highlight areas of equipoise by reviewing these planned and open trials. Current studies are addressing length of anticoagulant therapy, prophylaxis in leukemia, catheter-related thrombosis, and thrombolysis versus anticoagulation for proximal deep vein thrombosis.

KIDS-DOTT—Updates from a Randomized Controlled Trial Studying Length of Anticoagulant Therapy in Pediatric Thrombosis
Neil A. Goldenberg, MD PhD

Updates from ACCL1333—Apixaban in Pediatric Acute Lymphoblastic Leukemia (ALL)
Sarah H. O’Brien, MD MSC

Catheter-Directed Thrombolysis vs Anticoagulation for Proximal Lower Extremity Thrombosis: The PHLO Study
Marilyn Manco-Johnson, MD

Current Approaches to Clinical Trials in Catheter-Related Thrombosis in Children
Anjali Sharathkumar, MD MS

No relevant financial relationships to disclose; discussion of off-label drug use: Marilyn Manco-Johnson; Anjali Sharathkumar

Relevant financial relationships to disclose; discussion of off-label drug use: Cameron C. Trenor-Pfizer: Principal investigator, no compensation received; Neil A. Goldenberg-Johns Hopkins University: Principal investigator, funding; Sarah H. O’Brien- Bristol Myers Squibb: Principal investigator, research grant; Pfizer: Advisory board member, honoraria

(A3) Playing on Our Strengths—Developing Interprofessional Teams in Pediatric Hematology-Oncology
Room 519

Richard Tower, MD (Moderator); Brooke Bernhardt, PharmD MS BCOP; Kathleen Adlard, MN RN CNS CPON®

Objectives:

  1. Explore why interprofessional team development is important in patient care and the future of healthcare.
  2. Choose the elements of a high-functioning interprofessional team.
  3. Sketch the care of a complex hematology-oncology patient using an interprofessional team approach.
  4. Chart the structure of an interprofessional team at your institution.

The care of pediatric hematology-oncology patients requires a diverse set of healthcare professionals. Interprofessional collaboration between these individuals improves coordination of care, communication, and patient safety. However, the how- to of interprofessional team development is only infrequently incorporated into health professional training programs. In this session, we will introduce tools for interprofessional team development and allow participants to practice collaborative communication using real-world scenarios. This experience will encourage using interprofessional teams in daily practice.

No relevant financial relationships to disclose; discussion of off-label drug use: Brooke Bernhardt

No relevant financial relationships to disclose and no discussion of off-label drug use: Kathleen Adlard

Relevant financial relationships to disclose and no discussion of off-label drug use: Richard Tower- Abbott Labs: Family-employee, salary

4:45–5:20 pm or 5:30–6:05 pm

(SE02A/SE02B) Speed Mentoring
Room 525

Moderator: Mona D. Shah, MD; Sherif Badawy, MD

Speed mentoring is a series of short, focused conversations with a mentor about specific questions. It is a relatively new session concept that focuses on quick-hit information for time- efficient networking. Fellows and recent graduates registering for this Speed Mentoring session will have the opportunity to meet one-on-one with up to three mentors for 10 minutes each. Mentees will be contacted before the session and will be required to submit a one-page document prior to arriving in Montréal that addresses the focus of the speed mentoring session’s topic of interest (e.g., CV; abstract; specific aims of grant proposal; or preliminary data in the form of table, figure, poster draft, or design, etc.). Mentees should come prepared with two to three concrete questions to discuss for their chosen subject. Mentors will review mentees’ documents ahead of time for meaningful insight and efficient engagement. Mentees will be randomly assigned to one of two sessions taking place at 4:45–5:20 pm and 5:30–6:05 pm.

Advanced registration is required.

4:45–6:15 pm

Global Special Interest Group (GSIG)
Room 524

How to Incorporate Global Health into Your Career as a Pediatric Hematologist/Oncologist.

Co-chairs: Uma Athale, MD; Scott Howard, MD; Patrick McGann, MD MS; Andrea Orsey, MD

The mission of the GSIG is to improve the diagnosis, care, and outcomes for children with hematologic and oncologic disease across the world through the development of training partnerships and collaborative research. Advanced registration is recommended.

Diversity Special Interest Group (DSIG)
Room 519

Does Increasing Workforce Diversity Improve Disparities in Care Delivery?
Co-chairs: Emily R. Meier, MD MSHS; Jacqueline N. Casillas, MD MSHS

Dr. Isaac Odame will discuss how lack of diversity of pediatric hematologists/oncologists have contributed to the lack of hematopoietic stem cell transplants (HSCT) performed to cure pediatric patients with sickle cell disease and other healthcare disparities. With this foundational knowledge, workshop attendees will further develop this year’s workshop theme during the “Open Space” interactive networking sessions that follow. Funding for the Diversity SIG workshop is provided by a grant (R13CA213938) from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services, nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. government. The DSIG provides a national networking forum for members who are interested in promoting diversity in the field of pediatric hematology/oncology. The DSIG also aims to support the advancement of all ASPHO members and the field by broadly increasing diversity and inclusiveness in the membership and leadership of ASPHO, as well as in the home institutions of members.

Advanced registration is recommended.

6:15–7 pm

(SE03) International and First-Time Attendee Reception
Room 518AB

Advanced registration is required.

7–9:00 pm

Division Directors’ Meeting (DDM)
Room 515A

Advanced registration is required.

7:15–8:45 pm

Corporate Forum Dinner Symposium

Held at the Intercontinental Montréal Nordheimer Room, 5th Floor

Click here for details and registration.

Thursday, April 27

6:30–7:30 am

5K Fun Run/Walk

The Old Port of Montréal.

ASPHO is holding its fourth annual 5K Fun Run/Walk during the annual meeting at held at the Old Port of Montreal. Registration is $25 prior to April 27; race-day registration is $35. Registrants will receive a T-shirt. You can register when you register for the meeting. Exhibitors interested in participating, please contact This email address is being protected from spambots. You need JavaScript enabled to view it. .

6:30–8 am

Non-CME Breakfast Symposium
Room 520ABDE

Click here for details and registration.

7:00–8:15 am

Continental Breakfast
517 Foyer

8–9:30 am

(B4) Providing Optimal Pediatric Palliative Care: Overcoming the Barriers (M)
Room 519

Moderator: Kate A. Mazur, MSN RN CPNP

Objectives:

  1. Enhance the understanding and improve utilization of the concept of Concurrent Care.
  2. Identify strategies for identifying and referring patients to hospice and palliative care services as well as barriers to those referrals.
  3. Discuss patient and family personal experiences with hospice and palliative care services.

Recognition of the importance of pediatric palliative care has grown; however, a gap still exists in the consistent delivery of multidisciplinary palliative care to patients receiving disease- directed therapy. With the Affordable Care Act, pediatric palliative and hospice care can be provided along with concurrent disease-directed therapy, but providers’ lack of understanding of these services leads to inconsistent referral practices and confusion. This session addresses some of the common misunderstandings and aims to improve quality of care across the continuum.

Demystifying Concurrent Care
Tammy Kang, MD MSCE

Pediatric Palliative Care and Hospice Referrals: What Works and What Doesn’t
Christina K. Ullrich, MD MPH FAAHPM

No relevant financial relationships to disclose and no discussion of off-label drug use: Kate A. Mazur; Tammy Kang; Christina K. Ullrich

(B5) “When in Québec, Do What the Québecers Do…” (Part Deux)—It’s All about Platelets! (M)
Room 524

Moderator: Georges E. Rivard, MD

Objectives:

  1. Discuss recent research findings relevant to inherited platelet disorders, including their history, clinicopathologic features, suggested diagnostic and therapeutic approaches and molecular basis.
  2. Describe capabilities and limitations of currently available methods for platelet function testing and select a suitable diagnostic algorithm for suspected platelet dysfunction in children.
  3. Select appropriate antiplatelet agents and consequent dosing and laboratory monitoring options in pediatric patients.

Recent research has identified the molecular basis for several inherited platelet disorders and confirmed the utility of various new antiplatelet agents. However, the low frequency of these disorders and the challenges of platelet function testing contribute to a gap between contemporary research findings and clinical practice. Clinicians must possess a working knowledge of recent developments in platelet disorders, platelet function testing, and antiplatelet agents to optimize patient care within this niche arena of pediatric hematology.

Introduction
Georges E. Rivard, MD

Recent Research Developments in Inherited Platelet Disorders
Walter H. Kahr, MD PhD FRCPC

Laboratory Testing for Platelet Function Disorders: An Update
Sara J. Israels, MD

Antiplatelet Agents in Children: Indications and Monitoring
Alan D. Michelson, MD

No relevant financial relationships to disclose and no discussion of off-label drug use: Georges E. Rivard; Walter H. Kahr; Sara J. Israels

Relevant financial relationships to disclose; discussion of off-label drug use: Alan D. Michelson-Lilly: Co-investigator, research grant to institution

(B6) Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Pediatric Patients with ALL in the Era of Tyrosine Kinase Inhibitors, Novel Immunotherapies, and “MRD Status” (M)
Room 517D

Moderator: Valerie I. Brown, MD PhD; Julie An Talano, MD; Meret Henry, MD MS

Objectives:

  1. Discuss the impact of MRD status both pre- and post- SCT in patients with T-cell ALL.
  2. Describe the indications of allogeneic SCT for patients with Ph+ ALL in the era of BCR-ABL tyrosine kinase inhibitors.
  3. Identify appropriate candidates for immunotherapy pre- or post- SCT in pediatric patients with B-cell ALL. Allogeneic SCT can effectively treat patients with refractory/ relapsed ALL.

Allongeneic SCT can effectively treat patients with refractory/relapsed ALL. However, transplant-related morbidity/mortality and post-HSCT relapse remain significant limitations. With the advent of improved predictors of outcomes (e.g., MRD status) and innovative therapies such as targeted, biologically- relevant agents (e.g., BCR-ABL tyrosine kinase inhibitors) and immunotherapies (e.g., bispecfic T-cell engagers and CAR-T cell therapy), the indications and timing of HSCT for this patient population are evolving rapidly. Thus, pediatric hematology/ oncology providers need to understand how these novel therapeutic approaches and “MRD status” results are being integrated into SCT-based regimens.

MRD Status and Timing of SCT for Patients with ALL
Michael A. Pulsipher, MD

The Role of SCT for Patients with Ph+ ALL in the Era of BCR- ABL Tyrosine Kinase Inhibitors
Kirk R. Schultz, MD

The Timing of Immunotherapy and SCT for B-cell ALL
David Barrett, MD PhD

No relevant financial relationships to disclose and no discussion of off-label drug use: Valerie I. Brown; Julie An Talano; Meret Henry; Michael A. Pulsipher; David Barrett

Relevant financial relationships to disclose and no discussion of off-label drug use: Kirk R. Schultz-Juno: DSMB member, Honoraria; Mesoblast: DSMB member, Honoraria

9:45–11:15 am

(SE04) Award Presentations
Room 517D

St. Baldrick’s Foundation Robert J. Arceci Innovation Award Announcement

Frank A. Oski Memorial Lectureship

Alexis Thompson, MD MPH
Advances in the Hemoglobinopathies
Objectives:

  1. Review recent and potentially practice-changing clinical studies in sickle cell disease and thalassemia.
  2. Explore emerging opportunities to improve clinical care and advocacy in non-malignant hematology.

Dr. Alexis Thompson is currently the Hematology Section Head and holds the Sarah and A. Watson Armour Chai in Childhood Cancer and Blood Diseases at the Ann and Robert H. Lurie Children's Hospital of Chicago. She is also the President-Elect of the American Society of Hematology. She has a broad background in clinical and translational research, with extensive experience in investigator initiated as well as multicenter sutdies primarily in the thalassemia and sickle cell disease. Dr. Thompson will examine advances in nonmalignant pediatric hematology focused on sickle cell and thalassemia in the context of her career perspective and opportunities for advocacy. 

Relevant financial relationships to disclose; discussion of off-label drug use: Amgen/Baxalta/Blue Bird Bio:Celegene/ Eli Lilly/Mast/Novartis: Research support, investigator; Novartis/ApoPharma/Celgene: Honorarium, consultant

(4003-04) Young Investigator Award Presentations

Adam L. Green, MD

(4003) Mechanism of Action and Combination Therapy Studies on the XP01 Inhibitor Selinexor in Pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma

Objective: Optimize the clinical use of selinexor in pediatric high-grade glioma and diffuse intrinsic pontine glioma through preclinical studies focused on mechansim of action and combination therapy. 

Chandrika Gowda, MD

(4004A) Regulation of C-KIT Oncogene by Ikaros and Casein Kinase II (CK2) in T Cell Acute Lymphoblastic Leukemia (T-ALL) and (4004B) Lim Domain Only Protein 2 (LMO2) Expression Is Regulated by karos and Casein Kinase II (CK2) in Acute Lymphoblastic Leukemia

Objectives:

It has been hypothesized that expression of c-kit is necessary for leukemia stem cell survival and c-kit inhibitors have been tested for the treatment of human leukemia. The mechanisms that regulate c-kit expression in T-ALL remain unknown. Here, we present evidence that expression c-kit in T-ALL is regulated at the transciptional level by Ikaros, a tumor suppressor whose deletion is associated with T-ALL development.

Overexpression of LM02 in T-ALL is associated with poor prognosis. The mechanisms that regulate LM02 expression in T-ALL are still unknown. Ikaros is a tumor suppressor protein that is encoded by IKZF1, whose deletion is associated with development of T-ALL. Casein Kinase II (CK2) oncogene impairs Ikaros function which can be restored by using CK2 inhibitors. The objective of this study is to investigate the role of Ikaros and CK2 in regulation of LM02 in leukemia. 

No relevant relationships and no dicussion of off-label drug use. 

No relevant financial relationships and no discussion of off-label drug use: Adam L. Green; Chandrika Gowda

11:30 am–12:20 pm

ASPHO Business Meeting
Room 519

Enriching the Future Campaign Awards

12:30–1:30 pm

Non-CME Symposium

12:30–1:45 pm

(SE05) Early-Career Roundtable Luncheon
Room 515

Moderator: Vandy Black, MD MSc

Objectives:

  1. Discuss pathways to successfully achieve career development goals.
  2. Review the experiences of experts in the field.
  3. Provide trainees and early career members an opportunity to network with leaders in the field of pediatric hematology/oncology.

Attendees will participate in discussion groups led by experts in defined areas of interest. The purpose of this luncheon is to provide early-career professionals a forum to discuss issues one-on-one with leaders in the field, ask questions related to career development in a small-group setting, and receive positive reinforcement regarding career goals specific to their interests. One to two discussion leaders will be placed at each luncheon table, with the option for participants to switch tables for further discussion on a wide range of topics.

Advanced registration is required.

Basic Science/Translational Research
Douglas K. Graham, MD PhD; Daniel S. Wechsler, MD PhD; Kathleen M. Sakamoto, MD PhD

Clinician Educator
Timothy P. Garrington, MD; Caroline A. Hastings, MD; Jennifer C. Kesselheim, MD MEd

Clinical Research—Hematology
Jeffrey M. Lipton, MD PhD; George R. Buchanan, MD; Neil A. Goldenberg, MD PhD

Clinical Research—Oncology
Linda C. Stork, MD; William G. Woods, MD; Mark P. Atlas, MD; Patrick Leavey, MD; Patrick A. Brown, MD

Foreign Medical Graduates
Sarah R. Vaiselbuh, MD; Sinisa Dovat, MD PhD

Medical Students and Residents
Kimberly Whelan, MD MSPH; Thomas B. Russell, MD; Maria C. Velez, MD; Emily R. Meier, MD MSHS

No relevant financial relationships to disclose; discussion of off-label drug use: Douglas K. Graham-Meryx: Founder, stock

No relevant financial relationships to disclose and no discussion of off-label drug use: Vandy Black; Daniel S. Wechsler; Kathleen M. Sakamoto; Timothy P. Garrington; Caroline A. Hastings; Jennifer C. Kesselheim; Jeffrey M. Lipton; George R. Buchanan; Linda C. Stork; William G. Woods; Mark P. Atlas; Patrick Leavey; Patrick A. Brown; Sarah R. Vaiselbuh; Sinisa Dovat; Kimberly Whelan; Thomas B. Russell; Emily R. Meier

Relevant financial relationships to disclose and no discussion of off-label drug use: Maria C. Velez-CSLBehring: Speaker bureau, honoraria; NovoNordisk/Pfizer/Amgen/Octapharma: Principal investigator, research grant

Relevant financial relationships to disclose; discussion of off-label drug use: Neil A. Goldenberg-Johns Hopkins University: Principal Investigator, funding

12:30–2 pm

Advanced Practice Providers Special Interest Group (APP SIG)
Room 519

Co-chairs: Kate Mazur, MSN RN CPNP; Lesley Arland, PA; Nicholette Breier-Adkins, MSN RN CPNP

The Advanced Practice Provider Special Interest Group is dedicated to providing a forum for the exchange of ideas and information among advanced practice providers (APPs) and for promotion of their role in the field of pediatric hematology and oncology. Our inaugural meeting in 2016 identified a strong need for enhanced educational opportunities for this population. At this year’s meeting, results of a formal needs assessment will be reviewed, and specific educational programming will be developed for the coming year.

Advanced registration is recommended.

2–3:30 pm

(B7) Hemophilic Arthropathy, More than Meets the Eye: Advances in Early Disease Detection from Clinical Tools to Musculoskeletal Imaging
Room 524

Moderator: Nihal Bakeer, MD

Objectives:

  1. Describe the accuracy and utility of currently available clinical scoring tools and plain radiographs in the early detection of arthropathic changes in asymptomatic or mildly symptomatic patients with hemophilia.
  2. Provide an overview of the newest developments and applications of point-of-care musculoskeletal ultrasound in joint health surveillance and for early detection of joint disease in hemophilia.
  3. Discuss the risks, benefits and limitations of joint MRI in the diagnosis, follow-up and management of hemophilic arthropathy in the pediatric population.

Arthropathy is the most common and serious chronic complication of hemophilia and early intervention is vital. Using an interactive review of actual cases, this workshop will address the existing challenges and future directions in the evaluation of hemophilic arthropathy. The panelists will review the current knowledge on clinical scoring tools, radiography, and MRI and provide the audience with recent data on the utility of point-of- care musculoskeletal ultrasound in the detection of early joint disease.

Hemophilic Arthropathy, More than Meets the Eye: Advances in Early Disease Detection from Clinical Tools to Musculoskeletal Imaging
Nihal Bakeer, MD

Hemophilic Arthropathy: A Comprehensive Approach
Beverly Schaefer, MD

Point-Of-Care Musculoskeletal Ultrasound in Hemophilia: Will Sound Waves Replace or Complement Our Eyes?
Nihal Bakeer, MD

The Role of Magnetic Resonance Imaging (MRI) in Hemophilic Arthropathy: Who, When, Why?
Andrea Doria, MD PhD MSc

No relevant financial relationships to disclose and no discussion of off-label drug use: Nihal Bakeer; Beverly Schaefer

Relevant financial relationships to disclose and no discussion of off-label drug use: Andrea Doria- Novonordisk HealthCare Inc. /Terry Fox Foundation/Physician Services' Incorporation: Principal investigator, research grant; Bayer Healthcare Inc.: Consultant, research grant

(B8) ZFNs, CrispR/Cas9, and TALENS—Oh My! Deciphering the Alphabet Soup of Nuclease-Based Genome Editing and Its Clinical Applications (M)
Room 517D

Moderator: Valerie I. Brown, MD PhD; Daniel S. Wechsler, MD PhD

Objectives:

  1. Summarize the fundamental principles of nuclease-mediated genome editing.
  2. Recognize the potential clinical applications as well as the current limitations of nuclease-mediated genome editing.
  3. Appraise the ethical implications of the use of therapeutic genome editing. Novel gene therapy strategies have demonstrated preclinical and early clinical efficacy.

Novel gene therapy strategies have demonstrated preclinical and early clinical efficacy. However, their further development has been hampered by low integration frequency and the possibility of inappropriate integration into deleterious sites. Nuclease-based genome editing platforms (e.g., ZFNs, TALENS, and CrispR/Cas9) enable more precise, higher-efficiency repair of targeted genes. Because many pediatric hematology/ oncology–related disorders could benefit from these approaches, pediatric hematology/oncology providers need to understand these technologies and their clinical applications, as well as recognize their limitations and ethical implications of integrating these techniques into clinical practice.

A Primer on the Basic Scientific Principles of Nuclease- Mediated Genome Editing (M)

Mitchell Weiss, MD PhD

Therapeutic Genome Editing: Current and Future
Stuart Orkin, MD

Regulatory and Ethical Implications of Therapeutic Genome Editing
Christopher T. Scott, PhD

No relevant financial relationships to disclose and no discussion of off-label drug use: Valerie I. Brown; Daniel S. Wechsler; Mitchell Weiss; Christoper T. Scott; Stuart Orkin

(B9) Collaboration in the Treatment of Liver Tumors (M)
Room 519

Moderator: Howard M. Katzenstein, MD

Objectives:

  1. Define prognostic factors and the current risk stratification system for pediatric patients with liver tumors.
  2. Describe the current treatment recommendations, including surgical guidelines, for pediatric patients with liver tumors.
  3. Outline current international collaborations and resources for the treatment of pediatric liver tumors.

Pediatric livers tumors are rare and collaboration is necessary to best treat these tumors. Partnerships with surgeons optimize therapy and international collaborations have led to the identification of new prognostic factors and biological characteristics. Many oncologists are unaware of the nuances of current risk stratification and treatment procedures of these tumors. This session will update oncologists on the treatment, staging, and risk stratification of liver tumors and discuss a new online international consultation service.

Updates on Liver Tumors from the Children’s Oncology Group
Howard M. Katzenstein, MD

New Prognostic Factors and the Impact of International Therapeutic Strategies
Marcio Malogolowkin, MD

Surgical Decisions Based upon PRETEXT Staging
Gregory Tiao, MD

International Collaborations: PHITT (Pediatric Hepatic Malignancy International Therapeutic Trial-AHEP1531) and the International Online Consult Service
Allison O’Neill, MD

No relevant financial relationships to disclose; discussion of off-label drug use: Howard M. Katzenstein

No relevant financial relationships to disclose and no discussion of off-label drug use: Gregory Tiao; Allison O’Neill; Marcio Malogolowkin

3:45–4:45 pm

(PS4005-16) Concurrent Paper Sessions

Objectives:

  1. Discuss new approaches related to diagnosis and treatment in pediatric hematology/oncology.
  2. Examine current research outcomes from a variety of the latest in basic and clinical research.

Leukemia
Room 517D

Moderators: Christopher C. Porter, MD and Valerie I. Brown, MD PhD

Chimeric Antigen Receptor (CAR)-Modified T Cells (CTL019) Induce Durable CNS Remissions in Children with CNS/Combined Bone Marrow and CNS Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia (4005)
Mala K. Talekar, MD

Preclinical Efficacy of Daratumumab for T-ALL (4006)
Karen Bride, MD PhD

Minimal Residual Disease Assessment of Remission after Induction Therapy is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group (COG) (4007)
Sumit Gupta, MD PhD

Mertk is a Potential Therapeutic Target in Early Thymic Precursor Acute Lymphoblastic Leukemia (4008)
Ryan J. Summers, MD

No relevant relationships and no discussion of off-label drug use: Ryan J. Summers; Sumit Gupta

No relevant relationships, discussion of off-label drug use: Karen Bride; Mala K. Talekar

Solid Tumors/Lymphoma
Room 519

Moderators: Linda McAllister-Lucas, MD PhD and Nobuko Hijiya, MD

Risk Adapted Therapy Utilizing Upfront Brentuximab Vedotin (Bv) and Rituximab (R) with Reduced Toxicity Chemotherapy in the Treatment of Children, Adolescents and Young Adults (CAYA) with Newly Diagnosed Hodgkin Lymphoma (HL) (4009)
Jessica Hochberg, MD

Excellent Outcomes following Response-based Omission of Radiotherapy in children and Adolescents with Intermediate or Advanced Stage Hodgkin Lymphoma (4010)
Nmazuo Ozuah, MBBS

Targeting Integrin-mediated Signaling in Metastatic Ewing Sarcoma (4011)
Jade Wulff, MD

The Transcriptional Co-activator TAZ is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis (4012)
Michael Deel, MD

No relevant relationships and no discussion of off-label drug use: Jessica Hochberg; Nmazuo Ozuah; Jade Wulff; Michael Deel

Hematology I
Room 524

Moderators: Lindsay Mize, MSN RN CPNP and Emily R. Meier, MD

Decreased Microvascular Perfusion is a Physiological Biomarker of Vaso-occlusive Crisis due to Mental Stress and Pain Anticipation in Sickle Cell Disease (4013)
Saranya Veluswamy, MD

Realizing Effectiveness across Continents with Hydroxyurea (REACH): Enrollment and Baseline Characteristics (4014)
Patrick McGann, MD MS

Reduced Glutamate Channel Phosphorylation in Pain-related Brain areas in a Transgenic Model of Sickle Cell Disease (4015)
Dana M. LeBlanc, MD

Quick Start Hydroxyurea Initiation project (Q-SHIP): Targeted Education after Crisis to Increase the use of Hydroxyurea in Children with Sickle Cell Anemia (4016)
Lydia H. Pecker, MD

No relevant relationships and no discussion of off-label drug use: Saranya Veluswamy; Dana M. LeBlanc; Lydia H. Pecker

No relevant relationships, discussion of off-label drug use: Patrick McGann

5–6:30 pm

(B10) Beyond Antibodies and CAR T Cells: Challenges and Opportunities in Manipulating the Pediatric Cancer Immunome
Room 517D

Moderator: Timothy P. Cripe, MD PhD

Objectives:

  1. Describe the mechanisms of action, predictive biomarkers and adverse events of T cell checkpoint inhibitors and their rationale therapeutic combinations.
  2. Discuss how myeloid cells affect cancer growth and cancer therapy, and how they might be therapeutically targeted.
  3. Identify strategies to enhance the function of anticancer antibodies and CAR T cells.

The emerging successes of antibodies and cellular therapies highlight the power of the immune system. The immunologic landscape of cancer also involves numerous innate and adaptive immune mechanisms such as tumor-associated macrophages, NK cells, and T-cell checkpoints that are emerging as bone fide cancer biomarkers and therapeutic targets. We will discuss and review pediatric perspectives on these emerging mechanisms’ roles, giving the participants practical knowledge for studying and deploying the next generation of cancer immunotherapies.

Team Building with New Players in Cancer Therapy: Oncolytic HSV, TAM, PD1, CAR T
Timothy P. Cripe, MD PhD

Targeting Tumor-Associated Macrophages to Enhance Effectiveness of Immune Checkpoint and Other Immunotherapies
Shahab Asgharzadeh, MD

Integrating Combined Immunotherapy Strategies into Comprehensive Cancer Therapy: Harnessing Innate and Adaptive Immunity
Paul M. Sondel, MD PhD

Harnessing the Power of the Immune System: CARs Are Only the Beginning
David Barrett, MD PhD

No relevant financial relationships to disclose and no discussion of off-label drug use: Timothy P. Cripe; Shahab Asgharzadeh; Paul M. Sondel; David Barrett

(B11) Blood Clots in Sick Kids: A Critical Mini-Review of Venous Thromboembolism in Selected High-Risk Pediatric Populations (M)
Room 524

Moderator: Riten Kumar, MD MSC

Objectives:

  1. Discuss pathways to successfully achieve career development goals.
  2. Review the experiences of experts in the field.
  3. Provide trainees and early career members an opportunity to network with leaders in the field of pediatric hematology/oncology.

Venous thromboembolism (VTE) increasingly is being recognized in children, often as a complication of complex medical conditions, such as congenital heart disease, nephrotic syndrome, inflammatory bowel disease, sickle cell anemia, etc. Up front management, the duration of therapy, and the role of thromboprophylaxis in these high-risk cohorts may be nuanced. This interactive case-based session will equip participants with up-to-date, evidence-based knowledge on the epidemiology, clinical presentation, and management of VTE in selected high- risk populations, using a focused mini-review approach.

Thrombosis in Sickle Cell Anemia
Riten Kumar, MD MSC

Thrombosis in Nephrotic Syndrome
Bryce A. Kerlin, MD

Thrombosis in Inflammatory Bowel Disease
Anthony K. C. Chan, MBBS FRCPC

Thrombosis in Single Ventricle Physiology
Yaser Diab, MBBS

No relevant financial relationships to disclose and no discussion of off-label drug use: Riten Kumar; Anthony K. C. Chan; Yaser Diab

Relevant financial relationships to disclose; discussion of off-label drug use: Bryce A. Kerlin-Bayer Healthcare US: Advisory board member, honoraria; CSL Behring Foundation: Principal investigator, research grant; Novo Nordisk/Baxalta: Advisory board member, Honoraria

(B12) It’s Not Just About Diversity: Improving the Outcomes for All by Moving Toward Equity (M)
Room 519

Moderator: Stephen C. Nelson, MD

Objectives:

  1. Increased awareness of how cultural and racial differences affect health outcomes.
  2. Improved understanding of how our biases affect patient trust and outcomes and develop tools for improvement.
  3. Develop strategies to increase diversity within our field.

Racial healthcare inequity is most certainly a multifactorial problem. Barriers to healthcare equity include the healthcare system (insurance, funding, whiteness, social determinants), the patient (poor health literacy, fear, mistrust), the community (awareness, advocacy), and healthcare providers (unconscious bias, attitudes, racism, stereotyping). We need to increase our awareness of these issues and how they negatively impact our patients of color. We, as medical care providers, potentially have the greatest power to address our biases to help close the gap for our underrepresented and marginalized families.

Race as an Independent Factor in Health Outcomes—How Implicit Bias Affects Care
Stephen C. Nelson, MD

An International Perspective on Healthcare Access and Disparities
Isaac Odame, MD

The Importance of Diversity Among Healthcare Providers to Improve Racial Disparities in Health Outcomes
Jacqueline Casillas, MD MSHS

No relevant financial relationships to disclose and no discussion of off-label drug use: Stephen C. Nelson; Jacqueline Casillas
 
Relevant financial relationships to disclose and no discussion of off-label drug use: Isaac Odame- Novartis: Advisory, Honoraria; Apopharma: Advisory, Honoraria; Global Blood Therapeutics: Advisory, Honoraria; Pfizer: Advisory, Honoraria

6:30–7:30 pm

Author-Attended Poster Session A
Room 516-517ABC

Odd-numbered posters

6:30–8 pm

(SE06) Grand Opening Reception with Exhibits and Posters
Room 516-517 ABC

7:30–9 pm

Fellowship Program Directors’ Meeting (PDD)
Room 515AB

Advance registration is required.

Friday, April 28

7-9 am

Continental Breakfast in Exhibit Hall
Room 516-517ABC

7 am–2:45 pm

Exhibit Hall Open for Poster Viewing

7:30-8 am

Odd-Numbered Poster Tour
Room 516-517ABC

This year, ASPHO will provide two poster tours during exhibit hours. The Program Committee will select five highly ranked posters and provide a 30-minute tour for all interested attendees. Authors of these selected posters will have the opportunity to provide a brief overview of their research and attendees will be able to ask questions. No sign-up is needed. Attendees should plan to meet at the Exhibit Hall entrance and look for a member of the Program Committee holding a "Poster Tour" sign. Don’t miss the opportunity to receive a quick overview of top- rated abstracts.

Plan to arrive at 7:20 am. 

8–9 am

Concurrent Paper Sessions

Children’s Oncology Group
Room 517D

Moderator: Patrick A. Brown, MD

Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia based on Blast Genetics at Diagnosis: A Report from the Children’s Oncology Group (4017)

Mignon Loh, MD

Effects of Sodium Thiosulfate on Prevention of Cisplatin-Induced Hearing Loss in Children with Cancer: Results of the Randomized Controlled Trial ACCL0431 (4018)
David R. Freyer, DO MS 

COG Neuroblastoma Clinical Trials: Recent Data and Future Plans (4019)
Julie Park, MD

Stem Cell Transplantation—Advancing the Field Through Collaboration (4020)
Michael Neider, MD

No relevant relationships and no discussion of off-label drug use: Mignon Loh; David R. Freyer

No relevant relationships, discussion of off-label drug use: Julie Park

Relevant relationships; discussion of off-label drug use: Michael Neider

Outcomes Research
Room 524

Moderators: Karen E. Effinger, MD MS, and Rochelle Maxwell, MD

Ruxolitinib in Pediatric Patients with Severe of Refractory Graft-Versus-Host Disease: A Single-Institution Case Series (4021)
Julie R. Boiko, MD MS

Patient and Parent Experience of Cancer Symptoms as Assessed by the Memorial Symptom Assessment Scale for Children (4022)
Hayden Leeds, BA

Impact of Ethnicity and Education Level on Parental Preferences for Information Giving and Decision Making in the Pediatric Cancer Setting (4023)
Katie Bergstrom, MS CGC

Processing Speed and Academic Fluency in Youth with Sickle Cell Disease (4024)
Molly Gardner, PhD

No relevant relationships and no discussion of off-label drug use: Hayden Leeds; Katie Bergstrom; Molly Gardner

No relevant relationships, discussion of off-label drug use: Julie R. Boiko

9:15–10:45 am

(C13) Social Media: The Good, the Bad, and Beyond (M)
Room 519

Moderator: Mona D. Shah, MD; Vandy Black, MD MSc; Dominder Kaur, MD

Objectives:

  1. Introduce the concept, the challenge of defining, and the increasing scope of social media.
  2. Provide an overview of types of social media currently utilized by providers and educators in the healthcare delivery network.
  3. Engage attendees in discussions regarding the pros and pitfalls of social media in healthcare delivery and discuss legal and ethical considerations including ownership of content, patient and provider privacy, effects on personal and patient engagement/communication, etc.

Understanding the benefits of social media can be an invaluable asset to a post-doctoral clinical fellow becoming a junior faculty member or to a senior level educator in engaging a younger audience. However, it also is important to be cognizant of the legal/ethical considerations when discussing/using social media in the context of the patient-provider relationship, the transfer of information between providers, and how it may blend into external work-personal relationships. This session will enable honest dialogue using small-group discussions and a series of case vignettes. The moderators will emphasize strengths of and obstacles to overcome when engaging with social media.

No relevant financial relationships to disclose and no discussion of off-label drug use: Mona D. Shah; Vandy Black; Dominder Kaur

(C14) Sickle Cell Disease in the AYA Population: Management Challenges for the Pediatric Hematologist
Room 524

Moderator: Lindsay Mize, MSN RN CPNP; Emily R. Meier, MD MSHS

Objectives:

  1. Improved understanding of management techniques for priapism.
  2. Develop strategies for management of chronic pain in SCD associated with vasocclusive crisis and AVN.
  3. Describe contraceptive options for the AYA population with SCD and best practices for hydroxyurea use.

Survival of children with sickle cell disease (SCD) has improved over the past 30 to 40 years thanks to early identification of affected infants through newborn screening, early institution of penicillin prophylaxis, and family education. Despite the increased utilization of hydroxyurea in childhood, end organ damage continues to occur, resulting in morbidity and decreased quality of life as patients age. Pediatric hematologists often lack experience caring for chronic problems that more commonly are associated with adult patients, despite taking care of the adolescent and young adult (AYA) population. This session will address three common AYA SCD-related issues.

Priapism

Serge Carrier, MD

Novel Mechanisms of Chronic Pain in Sickle Cell Disease

Amanda Brandow, DO MS

Reproductive Issues for People Living with SCD

Kim Smith-Whitley, MD

No relevant financial relationships to disclose and no discussion of off-label drug use: Lindsay Mize Emily R. Meier; Amanda Brandow

Relevant financial relationships to disclose; discussion of off-label drug use: Serge Carrier-Pfizer Canada: Advisory board member, honoraria; Eli Lilly Canada: Speaker Bureau, Educational Grant; Coloplast: Protorship, honoraria; Kim Smith-Whitley- Pfizer: Advisory Board Member; Cerus: Consultant

(C15) Molecularly Defined Rare Pediatric Sarcomas: An Update for the General Oncologist
Room 517D

Moderator: Rajkumar Venkatramani, MD MRCPCH MS

Objectives:

  1. Discuss the approach to a pediatric patient with a rare sarcoma.
  2. Review the latest molecular diagnostic tools for accurate diagnosis of soft tissue sarcoma.
  3. Review the role of chemotherapy and targeted therapy in the management of three molecularly defined pediatric sarcomas.

As a result of rapid advances in molecular diagnostic techniques, soft tissue sarcomas increasingly have been classified on the basis of underlying molecular alterations. This workshop will focus on three molecularly defined pediatric sarcomas and update the audience on latest advances in diagnosis and management of these tumors. We will present examples of some early successes in targeted therapy. After this session, attendees will have a better understanding of the principals of managing these tumors.

Alveolar Soft Part Sarcoma
Rajkumar Venkatramani, MD MRCPCH MS

Infantile Fibrosarcoma
Noah Federman, MD

Undifferentiated Round Cell Sarcoma with CIC-DUX4 and BCOR Gene Abnormalities
Cristina Antonescu, MD

No relevant financial relationships to disclose and no discussion of off-label drug use: Rajkumar Venkatramani; Noah Federman; Cristina Antonescu

10:45–11:15 am

Even-Numbered Poster Tour
Room 516-517ABC

This year, ASPHO will provide two poster tours during exhibit hours. The Program Committee will select five highly ranked posters and provide a 30-minute tour for all interested attendees. Authors of these selected posters will have the opportunity to provide a brief overview of their research and attendees will be able to ask questions. No sign-up is needed. Attendees should plan to meet at the Exhibit Hall entrance and look for a member of the Program Committee holding a "Poster Tour" sign. Don’t miss the opportunity to receive a quick overview of top- rated abstracts.

Plan to arrive at 10:35 am.

10:45–11:45 am

Break in Exhibit Hall

11:15–11:45 am

Education Theater in Exhibit Hall

Click here for details and registration.

11:45 am–1:15 pm

(C16) Mechanisms of Tumor Microenvironment Immune– Mediated Resistance and Methods of Therapeutic Circumvention (M)
Room 524

Moderator: Mitchell S. Cairo, MD

Objectives:

  1. Identify mechanism(s) of T-cell activation and inhibition and discuss new therapeutic approaches of checkpoint blockade in pediatric cancers.
  2. Increase our understanding of mechanism(s) TGFB-1 inhibition by the innate immune response in Neuroblastoma and new methods of circumvention.
  3. Describe the mechanisms of resistance to immunotherapy in childhood ALL, and to suggest strategies to overcome resistance for therapeutic benefit.

The tumor microenvironment recently has been identified to regulate the immune response to a variety of malignancies. A number of mechanisms including T-cell checkpoint blockade, TGFB-1 inhibition, and receptor downregulation have been identified as key components of suppressing immune responses to a number of malignancies. Pediatric oncologists and mentees in training have limited information regarding the mechanisms, pathophysiology, and methods of circumvention of immunosuppression by the tumor microenvironment.

Regulation of T-Cell Mediated Tumor Immunology by Checkpoint Blockade
Mitchell S. Cairo, MD

The Role of TGFB-1 in Immune Suppression of Neuroblastoma
Robert C. Seeger, MD MS

Resistance to Immunotherapy in Childhood Acute Lymphoblastic Leukemia: Mechanisms and Strategies to Overcome
Patrick A. Brown, MD

No relevant financial relationships to disclose and no discussion of off-label drug use: Robert C. Seeger; Patrick A. Brown

Relevant financial relationships to disclose and no discussion of off-label drug use: Mitchell S. Cairo-Jazz Pharmaceuticals/Gilead/Celgene/Roche: Advisory board member, honoraria; Sanofi: Speaker bureau, honoraria

(C17) Behind the Scenes at Pediatric Blood & Cancer: Everything You Always Wanted to Know About Getting Published
Room 519

Moderator: Daniel S. Wechsler, MD PhD

Objectives:

  1. Describe the review process for a submitted manuscript.
  2. Identify what reviewers and editors consider as they review manuscripts.
  3. Recognize which types of manuscripts are most appropriate for which journals.

Although scientific publication is a critical component of academic medicine and is essential for career advancement, there is little formal instruction on how the publication process actually works. Peter E. Newburger, MD, and Thomas Gross, MD PhD, the editors of Pediatric Blood & Cancer, the premier journal in our field, will provide their insights into the editorial and review process to help trainees and junior faculty enhance the likelihood of successfully getting published.

Tips on Navigating the Review Process from a Reviewer’s Perspective
Peter E. Newburger, MD; Thomas Gross, MD PhD

No relevant financial relationships to disclose and no discussion of off-label drug use: Daniel S. Wechsler; Peter E. Newburger; Thomas Gross

(C18) New Insights in Inherited Hematologic Diseases (M)
Room 517D

Moderator: Clifford Takemoto, MD

Objectives:

  1. Discuss the utility of next generation sequencing for FVIII and FIX genes.
  2. Describe the characteristic of individuals with GATA2 mutations.
  3. Summarize the role that PIKC3A mutations play in the development of lymphatic malformations.

Advances in technologies to DNA sequencing have aided the discovery of the genetic basis for many inherited hematologic diseases. In addition, detailed genotype/ phenotype mapping of known genes is feasible for clinical outcomes. Pediatric hematologists/oncologists may not have the most recent information regarding genes that cause inherited myelodysplastic syndrome or vascular malformations. In addition, they may not have current knowledge of the genotype/phenotype information that is being studied in hemophilia A and B.

New genetic information is accumulating at a rapid pace. How genetic information about well-characterized conditions such as hemophilia may impact clinical phenotypes will be of value to practitioners. For patients with bone marrow failure, providers’ knowledge of the genetic basis may impact prognosis and treatment approach. The genetics of vascular malformations is a rapidly advancing field and an understanding of mutations in signaling pathways can lead to pharmacologic strategies for treatment.

New Insights in Congenital Hematologic Diseases
Steven M. Holland, MD

My Life, Our Future Project
Jill M. Johnsen, MD

Genetic Discovery in Vascular Anomalies: Progress in Diagnosis and Treatment for the Future
Matthew Warman, MD

No relevant financial relationships to disclose and no discussion of off-label drug use: Matthew Warman; Steven M. Holland

Relevant financial relationships to disclose and no discussion of off-label drug use: Jill Johnsen-CSL Behring: Consultant, honoraria; Clifford Takemoto- NovoNordisk/Mast Therapeutics/Baxalta: Grant support, PI

1:15–2:15 pm

Author-Attended Poster Session B
Room 516-517ABC

Even-numbered posters

1:15–2:45 pm

(SE07) Lunch in Exhibit Hall Exhibits and Posters

2–2:30 pm

Education Theater in Exhibit Hall

Click here for details and registration.

2:35 pm

Passport Prizes Announced

2:45–4:15 pm

(C19) Changing Workforce of Pediatric Hematology/Oncology
Room 524

Moderators: Jeffrey Hord, MD; Patrick Leavey, MD; Alan S. Wayne, MD; Elizabeth Villavicencio; Rachel Thienprayoon; Michelle Hermiston; Ayesha Zia; Adam L. Green

Objectives:

  1. Recognize the scope of changes occurring at a national level in our sub-specialty.
  2. Identify challenges around matching number of trainees with number of jobs open.
  3. Envision potential new training, employment and staffing models within the PHO field.

Pediatric hematologists/oncologists and ASPHO see that the pediatric hematology/oncology workforce is changing. In 2015, based on data collected by the ASPHO Practice Committee and the Workforce Task Force, ASPHO formed the Workforce Strategy Advisory Group to synthesize data and share this information with the field. In this session, speakers will summarize the findings of that group.

No relevant financial relationships to disclose and no discussion of off-label drug use: Jeffrey Hord; Patrick Leavey; Adman L. Green; Rachel Thienprayoon; Michelle Hermiston; Elizabeth Villavicencio

Relevant financial relationships to disclose; discussion of off-label drug use: Ayesha Zia- Shire/Octapharma: Advisory Board Member, honoraria

(C20) New Diagnostic and Therapeutic Approaches of Opportunistic (Viral/Fungal) Infections in the Pediatric Cancer Patient (M)
Room 517D

Moderator: Mitchell S. Cairo, MD

Objectives:

  1. Delineate the risk factors associated with opportunistic viral and fungal system infections in the immunocompromised pediatric cancer patients.
  2. Identify the safety and efficacy of anti-fungal antibiotics in immunosuppressed pediatric cancer patients.
  3. Increase our understanding of new antiviral antibiotics in the treatment of respiratory viral diseases in immunocompromised pediatric cancer patients.

Pediatric cancer patients are at high risk for developing opportunistic viral and fungal systemic infections. Recent advances have been made in identifying the risk factors as well as new antiviral and antifungal antibodies and genetically re- engineered immune cells to treat these high-risk opportunistic viral and fungal systemic infections. Pediatric hematologists/ oncologists and mentees in training have limited information on the risk factors of and uses for new antimicrobial drugs and genetically re-engineered immune cells to treat these infections.

Overview and Risk Factors of Opportunistic Infection in the Pediatric Cancer Patient
Nobuko Hijiya, MD

New Therapeutic Approaches in Systemic Fungal Infections
Lillian Sung, MD PhD

Diagnosis and Potential Treatment of Respiratory Viruses in the Immunocompromised Host
Janet Englund, MD

Multiviral Cytotoxic T-Lymphocytes in the Treatment of Systemic Viral Infections
Catherine Bollard, MD MBChB

No relevant financial relationships to disclose and no discussion of off-label drug use: Lillian Sung; Catherine Bollard

Relevant financial relationships to disclose and no discussion of off-label drug use: Mitchell S. Cairo- Jazz Pharmaceuticals/Gilead/Celgene/Roche: Advisory board member, honoraria; Sanofi: Speaker bureau, honoraria; Nobuko Hijiya- Novartis: Consultant, Honoraria; Amgen - Advisory board member, honoraria

Relevant financial relationships to disclose; discussion of off-label drug use: Janet Englund- Pfizer/Gilead: Consultant, honorarium; GlaxoSmithKline/Pfizer/Alios: Principal Investigator, Research Grant

(C21) New Mutations and Targeted Therapies in Langerhans Cell Histiocytosis (LCH)
Room 519

Moderator: Ashish Kumar, MD PhD

Objectives:

  1. Describe the mutations and pathophysiology of LCH.
  2. Describe the targeted therapies available, their efficacies and limitations.
  3. Identify individualized treatment algorithms for patients with refractory/recurrent disease.

Recent discoveries have revolutionized our understanding of the pathogenesis of LCH and related histiocytic diseases and opened up avenues for targeted therapies. However, we have limited data on the safety and efficacy of these newer targeted therapies in children with LCH. The decision on when and how to utilize which agent is a complex one. The goals of this workshop are to review (1) the results of mutational studies and the pathophysiology of LCH, (2) available targeted therapies and the preliminary efficacy results, and (3) treatment algorithms for refractory/recurrent disease, including second- and third-line chemotherapy agents and targeted therapies.

When and How to Use Targeted Therapies in Children with Histiocytosis
James A. Whitlock, MD

Targeted Therapies in Histiocytic Disorders: Current Experience in Adults
Julien Haroche, MD

BRAF Mutation in CNS LCH: No Brainer for Targeted Therapy
Kenneth McClain, MD PhD

No relevant financial relationships to disclose; discussion of off-label drug use: Ashish Kumar; Kenneth McClain

No relevant financial relationships to disclose and no discussion of off-label drug use: Julien Haroche

Relevant financial relationships to disclose; discussion of off-label drug use: James A. Whitlock- Novartis: Principal Investigator, research grant

4:30–6 pm

(C22) Presidential Symposium: Physician, Sustain Thyself: Building Resilience to Prevent Burnout in a Complex World
Room 517D

Introduction: Amy L. Billett, MD Moderator: John D. Mahan, MD; Carolline A. Hastings, MD; Akiko Shimamura, MD PhD; Eric S. Sandler, MD; Glen Lew, MD

Physician burnout is a complex issue within the pediatric hematology/oncology workforce that can affect patient care, professionalism, physician care and safety, and the healthcare system. A growing body of evidence shows successes using multiple strategies, both personal and organizational, to build physician resilience to prevent and/or decrease burnout. This session will incorporate audience self-assessment, a didactic presentation, and a panel discussion to provide attendees with the tools needed to prevent and decrease burnout, promote personal resilience, and maintain a healthy environment for healthcare providers and their patients.

No Relevant financial relationships to disclose and no discussion of off-label drug use: Amy L. Billett; John D. Mahan; Carolline A. Hastings, MD; Akiko Shimamura, MD PhD; Eric S. Sandler, MD; Glen Lew, MD

6:15–7:15 pm

Distinguished Career Award Presentation and Reception
Room 517D

Saturday, April 29

6:45-7:45am

Hemoglobinopathy Special Interest Group
Room 519

Co-Chairs: Howard Grodman, MD; Monica Hulbert, MD

Small Program Special Interest Group
Room 524

Andrea M. Watson, MD; Sarah Vaiselbuh, MD

6:45-8:15 am

Continental Breakfast

8–9:30 am

(D23) Practicing Precision in Pediatric Oncology: Three Perspectives
Room 524

Moderator: Susan I. Vear, MD

Objectives:

  1. Assess genomic testing approaches to identify appropriate therapies.
  2. Apply population-based genome epidemiology to individualize patient care.
  3. Interpret and manage secondary findings revealed through genomic testing.

“Precision medicine” is a broad term which, in pediatric oncology, can be applied to everything from cancer diagnosis to treatment. As our understanding of the genomics of cancer development and treatment progresses, the challenge for the clinical provider is how to translate new data to patient care. This workshop provides an overview of this challenge and three perspectives on how to use the latest discoveries to make pediatric oncology a more precise practice.

Challenges and Strategies in Bringing Precision Medicine to Pediatric Oncology Practice
Susan I. Vear, MD

Applying Large N Data to Small N: Using Population Genetics for Clinical Care
Lara Sucheston-Campbell, PhD

Cancer Genomics in Pediatric Oncology Practice
Katherine A. Janeway, MD MMSc

Secondary Findings in Genomic Testing for Pediatric Oncology: Strategies for Interpretation and Management
Kami Wolfe Schneider, MS CGC

No relevant financial relationships to disclose and no discussion of off-label drug use: Susan I. Vear; Lara Sucheston-Campbell; Katherine A. Janeway; Kami Wolfe Schneider

(D24) What’s Happening in DC? A Look at ASPHO Advocacy Efforts
Room 519

Moderator: Jordan Wildermuth, MSW; Natasha Frederick, MD MPH; Naomi Luban, MD; Robert S. Nickel, MD

  1. Educate membership on advocacy practice, including commonly used language and the legislative process
  2. Describe ASPHO’s current federal policy advocacy activities and potential impact on pediatric hematology/oncology practice.
  3. Introduce ASPHO membership to advocacy skills with opportunity for direct application with policymakers.

ASPHO’s strategic plan states that ASPHO will be recognized by the global pediatric hematology/oncology community as advocating for pediatric hematology/oncology. The Board of Trustees has invested resources into revamping the Advocacy Committee, developing ASPHO’s advocacy priorities, and hiring staff to move ASPHO’s advocacy agenda forward. Attendees will understand the impact of policies affecting patients and the profession and how to engage in the advocacy process.

No relevant financial relationships to disclose and no discussion of off-label drug use: Jordan Wildermuth; Natasha Frederick; Naomi Luban; Robert S. Nickel

(D25) Critical Care of the Immunocompromised Pediatric Hematology/Oncology Patient
Room 517D

Moderator: Christine N. Duncan, MD MMSC; Julie An Talano, MD

Objectives:

  1. Discuss factors unique to immunocompromised pediatric hematology/oncology patients that should be taken into account when ECMO is considered.
  2. Discuss the role of noninvasive ventilation in this population in the context of the available literature and expert opinion.
  3. Increased knowledge of the use of renal replacement strategies in critically ill immunocompromised pediatric hematology/oncology patients.

Immunocompromised hematology or oncology patients often require critical care intervention because of their underlying disease or complications of therapy. The outcome for these patients has improved in recent years, but remains unacceptably low. In this workshop, we will discuss and debate changes in the critical care management of hematology, oncology, and hematopoietic cell transplant patients that may have led to improved survival. Topics will include the timing of critical care intervention, use of ECMO, non-invasive ventilation, and fluid management strategies.

Clinical Outcomes of Pediatric Hematology/Oncology Patients
Christine N. Duncan, MD MMSC

Ventilatory Management Strategies
Jennifer McArthur, MD

Use of ECMO

Robert Neibler, MD

No relevant financial relationships to disclose and no discussion of off-label drug use: Christine N. Duncan; Julie An Talano; Jennifer McArthusr; Robert Niebler

9:45–11:15 am

(4028) Concurrent Paper Sessions with Luminary Investigators

ASPHO has invited two recognized investigators, George Rivard, MD and Nada Jabado, MD PhD to present their laboratories' current cutting-edge research. These luminary speakers will present prior to the brain tumor and hematology concurrent platform sessions.

Objectives:

  1. Discuss new approaches related to diagnosis and treatment in pediatric hematology/oncology.
  2. Examine current research outcomes from a variety of the latest in basic and clinical research.

No relevant financial relationships to disclose and no discussion of off-label drug use: Georges Rivard

Brain Tumors
Room 524

Moderators: Kate A. Mazur, MSN BSN CPNP, and Denise M. Adams, MD

Pediatric High-Grade Brain Tumors: A Tale of a Histone Tail
Nada Jabado, MD PhD

Hematopoietic Origin and Targets for Therapy in CNS Langerhans Cell Histiocytosis: BRAF-V600E in Blood and Brain and Response to BRAF Inhibition Suggest Hematopoeitic Origin of Neurodegeneration in LCH (4025)
Olive S. Eckstein, MD

Molecular Subgrouping and Outcomes for Young Children with Newly Diagnosed Ependymoma Treated on the Multi-institutional SJYC07 Trial (4026)
Nicholas Whipple, MD

Safety and Tolerability of Combining the Ido-inhibitor Indoximod with Re-irradiation for Pediatric Patients with Progressive Brain Tumors Treated on the NLG-2105 PHASE 1 Trial (NCT02502708) (4027)
Theodore S. Johnson, MD PhD

Whole-exome sequencing study of Medulloblastoma cases to identify disease Associated Exonic Mutations (4028)
Matthew Gianferante, MD

No relevant relationships and no discussion of off-label drug use: Nada Jabado; Olive S. Eckstein; Matthew Gianferante

No relevant relationships, discussion of off-label drug use: Theodore S. Johnson; Nicholas Whipple

Hematology II
Room 519

Moderators: Clifford Takemoto, MD, and Cameron C. Trenor

Understanding Bleeding Disorders: A First Step in Treating Them
Georges Rivard, MD

The Genomic Landscape of Pediatric Myelodysplastic Syndromes (4029)
Jason Schwartz, MD PhD

Characteristics and Outcomes of Osteomyelitis in Children with Sickle Cell Disease: A Retrospective Review of a 10-year single-center experience (4030)
Julie Weisman, MD

Retrospective Study of Hematologic Complications in Vascular Malformation Patients with Localized Intravascular Coagulopathy Undergoing Sclerotherapy (4031)
Kiersten Ricci, MD

Clinical and Laboratory Outcomes Following Total or Partial Splenectomy in Patients with Hereditary Spherocytosis (4032)
Serena Tripodi, MD

No relevant financial relationships to disclose and no discussion of off-label drug use: Serena Tripodi; Georges Rivard; Jason Schwartz

No relevant relationships, discussion of off-label drug use: Kiersten Ricci; Julie Weisman

11:30 am–1 pm

Palliative Care Special Interest Group (PSIG)
Room 524

Co-chairs: Justin Baker, MD; Emma Jones, MD; Karen Moody, MD

How I Treat...a Palliative Oncology Subspecialty Panel Common issues related to the integration of palliative care into pediatric oncology will be addressed by pioneers and experts in the field. The mission of the Palliative Care SIG is to accelerate the availability of high-quality palliative care to pediatric oncology patients across the country. Advanced registration is recommended.

11:45 am–1:45 pm

(MOCS) Maintenance of Certification (MOC) Learning Session
Room 519

Glen Lew, MD (moderator); ZoAnn Dreyer, MD; Karen E. Effinger, MD MS; Emily R. Meier, MD MSHS; Sarah H. O’Brien, MD MSc; Michael A. Pulsipher, MD; Elizabeth Raetz, MD; Zora Rogers, MD; Sheila Weitzman, MD BCh FCP (SA) FRCP; Naomi Winick, MD

The MOC learning session will feature an American Board of Pediatrics (ABP) Lifelong Learning and Self-Assessment Module. It is intended not only for those who are enrolled in the MOC process and would like to earn MOC activity points, but also for anyone wishing for a broad review of recent literature relevant to pediatric hematology/oncology. The session will be conducted in an interactive group setting led by authors or experts in their fields. The session will cover multiple-choice questions in the 2017 Pediatric Hematology-Oncology Self-Assessment. Please bring your laptop to enter the answers to each question during the session. At the completion of this session, those enrolled in the ABP MOC program will submit their answers to the online module for scoring to receive 10 MOC Part 2 points and 3 AMA PRA Category 1 Credits™. Enrolled participants can access the module(s) online from the ABP website at www.abp. org. For additional information about ABP’s MOC program requirements, visit www.abp.org or call the ABP Contact Center at 919.929.0461. Please note that this is not a Board review activity; the workshop is designed to facilitate completion of ABP’s Lifelong Learning and Self-Assessment MOC requirement. Advanced registration is required.

The registration fee is $50.

No relevant financial relationships to disclose; discussion of off-label drug use: Zora Rogers; Sheila Weitzman

No relevant financial relationships to disclose and no discussion of off-label drug use: Glen Lew; ZoAnn Dreyer; Karen Effinger; Emily R. Meier; Michael A. Pulsipher; Elizabeth Raetz; Naomi Winick

Advertising, Exhibits, & Support | Career Center | Calendar | Contact Us
Terms of Use & Privacy Policy » © The American Society of Pediatric Hematology/Oncology